Afuco™ Anti-Human TNFRSF18 ADCC Therapeutic Antibody (TRX518), ADCC Enhanced
Anti-TNFRSF18 ADCC Enhanced Antibody (TRX518) is an ADCC enhanced antibody produced by our Afuco™ platform. TRX518, a novel, humanized monoclonal antibody that is designed to enhance the immune system's anti-tumor response. TRX518 is the first GITR-targeted therapeutic to enter human studies. TRX518 is currently being investigated for the treatment of cancer in a Phase 1 clinical trial.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-606CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | TNFRSF18 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at -20°C for long-term storage. Store at 4°C for up to one month. Avoid freeze/thaw cycles. |